Skip to main content
main-content

01.08.2011 | Original Paper | Ausgabe 4/2011

Cellular Oncology 4/2011

Tumor necrosis factor-α is associated with positive lymph node status in patients with recurrence of colorectal cancer—indications for anti-TNF-α agents in cancer treatment

Zeitschrift:
Cellular Oncology > Ausgabe 4/2011
Autoren:
M. Grimm, M. Lazariotou, S. Kircher, A. Höfelmayr, C. T. Germer, B. H. A. von Rahden, A. M. Waaga-Gasser, M. Gasser
Wichtige Hinweise
This paper is a reprint from ‘Tumor necrosis factor-α is associated with positive lymph node status in patients with recurrence of colorectal cancer indications for anti-TNF-α agents in cancer treatment, M. Grimm, M. Lazariotou, S. Kircher, A. Hfelmayr, C.T. Germer, B.H.A. von Rahden, A.M. Waaga-Gasser and M. Gasser’ originally published in Analytical Cellular Pathology/Cellular Oncology, Volume 33, number 3-4, 2010, pp. 151-163, IOS Press.
M. Grimm and M. Lazariotou contributed equally to this work.
An erratum to this article can be found at http://​dx.​doi.​org/​10.​1007/​s13402-011-0057-1

Abstract

Introduction

The progressive growth of malignancies is accompanied by a decline in the immune response through mechanisms which are poorly understood. Apoptosis and induction of inflammation by tumor released cytokines as tumor escape mechanisms have been proposed to play an important role in colorectal carcinogenesis.

Methods

Expression of Tumor necrosis factor-alpha (TNF-α) was analyzed in colorectal cancer specimen and the cancer cell line HT-29 by immunohistochemistry and RT-PCR. TNF-α expression on protein and mRNA level were correlated with clinical characteristics and impact on survival. TNFR-1 was co-labelled with TNF-α and CD8+ cytotoxic T cells in immunofluorescence double staining experiments. Results: 94% (n = 98/104) of the patients with CRC expressed TNF-α. High TNF-α expression was significantly associated with positive lymph node stage and recurrence of the tumor. Multivariate analysis revealed high TNF-α expression as an independent prognostic factor. Immunohistochemistry was correlated with RT-PCR results (т = 0.794). Immunofluorescence double staining experiments revealed increased TNFR-1 expression by CD8+ cells.

Conclusions

TNF-α expression by tumor cells may be an efficient immunological escape mechanism by inflammation-enhanced metastases and probably by induction of apoptosis in tumor-infiltrating CD8+ immune cells resulting in a down regulation of the tumoral immune response. Our data support the role of tumor-derived TNF-α expression as an important promoter of tumoral immune escape mechanisms and malignant progression, and suggest that analysis on either protein (immunohistochemistry) or RNA level (RT-PCR) can be used effectively in this respect. Targeting TNF-α may be a promising option, especially in cases with high TNF-α expression and positive lymph node metastases.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2011

Cellular Oncology 4/2011 Zur Ausgabe
  1. Sie können e.Med Innere Medizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Pathologie

14.03.2019 | Originalien | Ausgabe 2/2019

Medikamentennachweise bei bayerischen Altenheimbewohnern – eine rechtsmedizinische Analyse

Erste Ergebnisse aus Screeninguntersuchungen an Urinproben

07.03.2019 | Mammakarzinom | CME | Ausgabe 2/2019

Update der S3-Leitlinie Mammakarzinom

Was gibt es Neues für Pathologen?

21.02.2019 | Schwerpunkt: Neuropathologie | Ausgabe 2/2019

Neuropathologie der Medulloblastome und anderer embryonaler Tumoren des ZNS

Präzisierung der Diagnostik durch Integration genetischer Marker